BinaxNOW™
COVID-19 Ag
CARD HOME TEST
For use with anterior nasal swab specimens
For Use Under an Emergency Use Authorization (EUA) Only
For in vitro Diagnostic Use Only

INTENDED USE
The BinaxNOW COVID-19 Ag Card Home Test is a lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2. This test is authorized for non-prescription home use with self-collected observed anterior nasal (nares) swab samples from individuals aged 15 years or older with symptoms of COVID-19 within the first seven days of symptom onset. This test is also authorized for non-prescription home use with adult collected observed anterior nasal (nares) swab samples from individuals aged two years or older with symptoms of COVID-19 within the first seven days of symptom onset.
This test is also authorized for non-prescription home use with self-collected observed anterior nasal (nares) swab samples from individuals aged 15 years or older, or adult collected observed anterior nasal (nares) swab samples from individuals aged two years or older, with or without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over three days with at least 24 hours (and no more than 48 hours) between tests. The BinaxNOW COVID-19 Ag Card Home Test is to be performed only with the supervision of a telehealth proctor.

The BinaxNOW COVID-19 Ag Card Home Test does not differentiate between SARS-CoV and SARS-CoV-2.
Results are for the identification of SARS-CoV-2 nucleocapsid protein antigen. Antigen is generally detectable in anterior nasal (nares) swabs during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease.
Negative results should be treated as presumptive and confirmation with a molecular assay, if necessary, for patient management, may be performed. Negative results do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19.

For serial testing programs, additional confirmatory testing with a molecular test for negative results may be necessary, if there is a high likelihood of COVID-19, such as, an individual with a close contact with COVID-19 or with suspected exposure to COVID-19 or in communities with high prevalence of infection. Additional confirmatory testing with a molecular test for positive results may also be necessary, if there is a low likelihood of COVID-19, such as in individuals without known exposures to COVID-19 or residing in communities with low prevalence of infection.

Individuals who test negative and continue to experience COVID-like symptoms of fever, cough and/or shortness of breath may still have SARS-CoV-2 infection and should seek follow up care from their healthcare provider.

All healthcare providers will report all test results they receive from individuals who use the authorized product to relevant public health authorities in accordance with local, state, and federal requirements using appropriate LOINC and SNOMED codes, as defined by the Laboratory In Vitro Diagnostics (LIVD) Test Code Mapping for SARS-CoV-2 Tests provided by CDC.
The BinaxNOW COVID-19 Ag Card Home Test is intended for non-prescription self-use and/or, as applicable for an adult lay user testing another person aged 2 years or older in a non-laboratory setting. The BinaxNOW COVID-19 Ag Card Home Test is only for use under the Food and Drug Administration’s Emergency Use Authorization.

SUMMARY and EXPLANATION of the TEST
Coronaviruses are a large family of viruses which may cause illness in animals or humans. SARS-CoV-2 is an enveloped, single-stranded RNA virus of the β genus. The virus can cause mild to severe respiratory illness and has spread globally, including the United States.
The BinaxNOW COVID-19 Ag Card Home Test is a rapid lateral flow immunoassay for the qualitative detection of SARS-CoV-2 directly from nasal swabs, without viral transport media. The BinaxNOW COVID-19 Ag Card Home Test kit contains all components required to carry out an assay for SARS-CoV-2.

PRINCIPLES of the PROCEDURE
The BinaxNOW COVID-19 Ag Card Home Test is an immunochromatographic membrane assay that uses highly sensitive antibodies to detect SARS-CoV-2 nucleocapsid protein from nasal swab specimens. SARS-CoV-2 specific antibodies and a control antibody are immobilized onto a membrane support as two distinct lines and combined with other reagents/pads to construct a test strip. This test strip and a well to hold the swab specimen are mounted on opposite sides of a cardboard, book-shaped hinged test card.

To perform the test, a nasal swab specimen is collected under observation by or from the patient, then 6 drops of extraction reagent from a dropper bottle are added to the top hole of the swab well. The patient sample is inserted into the test card to construct the test strip. This test strip and a well to hold the swab specimen are mounted on opposite sides of a cardboard, book-shaped hinged test card.

To perform the test, a nasal swab specimen is collected under observation by or from the patient, then 6 drops of extraction reagent from a dropper bottle are added to the top hole of the swab well. The patient sample is inserted into the test card to construct the test strip. This test strip and a well to hold the swab specimen are mounted on opposite sides of a cardboard, book-shaped hinged test card.

To perform the test, a nasal swab specimen is collected under observation by or from the patient, then 6 drops of extraction reagent from a dropper bottle are added to the top hole of the swab well. The patient sample is inserted into the test card to construct the test strip. This test strip and a well to hold the swab specimen are mounted on opposite sides of a cardboard, book-shaped hinged test card.

To perform the test, a nasal swab specimen is collected under observation by or from the patient, then 6 drops of extraction reagent from a dropper bottle are added to the top hole of the swab well. The patient sample is inserted into the test card to construct the test strip. This test strip and a well to hold the swab specimen are mounted on opposite sides of a cardboard, book-shaped hinged test card.

To perform the test, a nasal swab specimen is collected under observation by or from the patient, then 6 drops of extraction reagent from a dropper bottle are added to the top hole of the swab well. The patient sample is inserted into the test card to construct the test strip. This test strip and a well to hold the swab specimen are mounted on opposite sides of a cardboard, book-shaped hinged test card.

To perform the test, a nasal swab specimen is collected under observation by or from the patient, then 6 drops of extraction reagent from a dropper bottle are added to the top hole of the swab well. The patient sample is inserted into the test card to construct the test strip. This test strip and a well to hold the swab specimen are mounted on opposite sides of a cardboard, book-shaped hinged test card.

To perform the test, a nasal swab specimen is collected under observation by or from the patient, then 6 drops of extraction reagent from a dropper bottle are added to the top hole of the swab well. The patient sample is inserted into the test card to construct the test strip. This test strip and a well to hold the swab specimen are mounted on opposite sides of a cardboard, book-shaped hinged test card.

To perform the test, a nasal swab specimen is collected under observation by or from the patient, then 6 drops of extraction reagent from a dropper bottle are added to the top hole of the swab well. The patient sample is inserted into the test card to construct the test strip. This test strip and a well to hold the swab specimen are mounted on opposite sides of a cardboard, book-shaped hinged test card.

To perform the test, a nasal swab specimen is collected under observation by or from the patient, then 6 drops of extraction reagent from a dropper bottle are added to the top hole of the swab well. The patient sample is inserted into the test card to construct the test strip. This test strip and a well to hold the swab specimen are mounted on opposite sides of a cardboard, book-shaped hinged test card.
INITIATING the TELEHEALTH VISIT
Upon receipt of the BinaxNOW COVID-19 Ag Home Test, the patient logs into NAVICA and selects, “I Already Have a Test Kit”. The home user then visits the telehealth provider website to start testing and waits in queue to connect to the telehealth proctor.

DIRECTIONS for RUNNING the BinaxNOW™ COVID-19 Ag CARD HOME TEST

DO NOT OPEN ITEMS UNTIL INSTRUCTED TO DO SO

Wash or sanitize your hands. Make sure they are dry before starting.

Set Up

It is recommended gloves (not provided) also be used during testing. Your box may contain more than one test kit. Use only 1 of each of the following for each test:

DO NOT open items until instructed.

1 Swab
1 Test Card
1 Bottle

or

REAGENTS and MATERIALS

Materials Provided (Your box may contain more than one test kit set)
Test Cards (1 or 2): A cardboard, book-shaped hinged test card containing the test strip
Extraction Reagent (1 or 2): Bottle containing <1 mL of extraction reagent
Nasal Swabs (1 or 2): Sterile swab for use with BinaxNOW COVID-19 Ag Card Home test

Materials Required but not Provided
Clock, timer or stopwatch
Smart Phone:* Apple is iOS11 or newer
Android is version 8 or newer

*Required to download the NAVICA app from the Google play store or Apple app store

PRECAUTIONS

1. For in vitro diagnostic use.
2. This product has not been FDA cleared or approved but has been authorized by FDA under an EUA.
3. Federal Law restricts this device to sale by or on the order of a licensed practitioner (US only).
4. This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens.
5. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
6. Proper sample collection and handling are essential for correct results.
7. Leave test card sealed in its foil pouch until just before use. Do not use if pouch is damaged or open.
8. Do not touch swab tip when handling the swab sample.
9. Do not use kit past its expiration date.
10. Do not mix components from different kit lots.
11. All kit components are single use items. Do not use with multiple specimens. Do not reuse the used test card.
12. Wash hands thoroughly or use hand sanitizer after handling.
13. Dispose of test kit components and patient samples in household trash.
14. INVALID RESULTS can occur when an insufficient volume of extraction reagent is added to the test card. To ensure delivery of adequate volume, hold vial vertically, 1/2 inch above the swab well, and add drops slowly.

This test does NOT determine if you had COVID-19 in the past or if you have immunity.

STORAGE and STABILITY

Store kit between 35.6-86°F (2-30°C). Ensure all test components are at room temperature before use. The BinaxNOW COVID-19 Ag Card Home Test is stable until the expiration date marked on the outer packaging and containers.
2 Open Pouch and Scan QR Code on Card
   If using a mobile device:
   ![QR Code Scanning]
   If using a computer:
   ![QR Code Scanning on Computer]

3 Open Card
   Card must stay FLAT on table for entire test.

   ![Card Opened]
   Top Hole
   Bottom Hole
   Result Window
   Test Strip
   DO NOT touch any parts on inside of card.

4 Apply Fluid to Top Hole
   A. Remove dropper bottle cap.
   B. Hold dropper bottle straight over TOP HOLE, not at an angle.
   C. Put 6 DROPS into TOP HOLE. Do not touch card with tip.

   ![Applying Fluid]
   6 drops

   Note: False negative results may occur if less than 6 drops of fluid is used.

5 Open Swab
   A. Open swab package at stick end.
   B. Take swab out.

   ![Swab Opened]
   Keep fingers away from swab end.
6 Swab Left Nostril
A. Insert the entire absorbent tip of the swab (usually 1/2 to 3/4 of an inch) into left nostril.
B. Firmly brush against insides of nostril in a circular motion 5 times or more for at least 15 seconds.

Up to 3/4 of an inch.

7 Swab Right Nostril
A. Remove swab and insert it into right nostril.
B. Firmly brush against insides of nostril in a circular motion 5 times or more for at least 15 seconds.

8 Insert Swab Into Bottom Hole
Keep card FLAT on table.
Insert swab tip into BOTTOM HOLE and firmly push up until tip fills TOP HOLE.

9 Turn Swab 3 Times
Keep card FLAT on table.
Turn swab to right 3 times in card and leave it in place.

Note: False negative results can occur if the nasal swab is not properly collected.

Note: False negative results can occur if the sample swab is not turned prior to closing the card.
**10 Peel Strip**
- DO NOT remove swab.
- Keep swab in place. Peel adhesive liner off.

**11 Close Card and Seal**
- DO NOT remove swab.
- Keep swab in place. Peel adhesive liner off.

**12 Wait 15 Minutes**
- DO NOT disturb card during this time.

**13 Scan QR Code**
- If using a mobile device:
- If using a computer:

**Note:** False results can occur if the card is disturbed/moved or test results are read before 15 minutes.
RESULT INTERPRETATION

There are three types of results possible. You will be instructed how to read each type in a specific order. Follow this order with your proctor:

1. Check for a Positive Result
2. Check for a Negative Result
3. Check for an Invalid Result

Check for Positive COVID-19 Result

Find result window and look carefully for two pink/purple lines in window.

• Positive Result: Two pink/purple lines will appear. One on the top half and one on the bottom half. COVID-19 was detected.

Check for Negative COVID-19 Result

Find result window and look for a single pink/purple line in window.

• Negative Result: A single pink/purple line on the top half where it says “Control.” COVID-19 was not detected.

A positive test result for COVID-19 indicates that antigens from SARS-CoV-2 were detected, and the patient is very likely to be infected with the virus and presumed to be contagious. Test results should always be considered in the context of clinical observations and epidemiological data (such as local prevalence rates and current outbreak/epicenter locations) in making a final diagnosis and patient management decisions. Patient management should follow current CDC guidelines.

A negative test result for this test means that antigens from SARS-CoV-2 were not present in the specimen above the limit of detection. However, a negative result does not rule out COVID-19 and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. The amount of antigen in a sample may decrease as the duration of illness increases. Negative results should be treated as presumptive and confirmed with a molecular assay, if necessary, for patient management.

For serial testing programs, additional confirmatory testing with a molecular test for negative results may be necessary, if there is a high likelihood of COVID-19, such as, an individual with a close contact with COVID-19 or with suspected exposure to COVID-19 or in communities with high prevalence of infection. Additional confirmatory testing with a molecular test for positive results may also be necessary, if there is a low likelihood of COVID-19, such as in individuals without known exposures to COVID-19 or residing in communities with low prevalence of infection.
Check for Invalid Result

If you see any of these, the test is invalid.

CONTROL

No lines seen
Blue control line only
Pink/purple sample line only
Blue control line AND pink/purple sample line

SAMPLE

Dispose In Trash

Reporting Patient Results Using the NAVICA app

Upon completion of the test and result interpretation by the user, the telehealth proctor will send the results to the user via the NAVICA app and the telehealth provider will report results to relevant public health authorities. The user will be notified by email and on their mobile device that their results are ready. The user will go to the results screen in NAVICA to obtain their results.

Note: If the patient does not have symptoms, a second test should be taken at least 24 hours (and no more than 48 hours) between tests.

If the BinaxNOW COVID-19 Ag Card Home Test result is Negative, the user will receive the following:
If the BinaxNOW COVID-19 Ag Card Home Test result is Positive, the user will receive the following:

Laura Test's COVID-19 test result is positive.

It is very likely that you have COVID-19 because proteins from the virus that causes COVID-19 were found in your sample at the time of your test.

BinaxNOW COVID-19 Test Details

Results Reported On
Dec 10, 2020 at 9:09 PM

Name
Laura Test

Test Result
Positive

Lot
112222A

Serial Number
XYIq0m1Lk6jAEnE9j5

CDC Guidelines
Self Quarantine. Proceed to your home and avoid contact with others.

Read more at CDC.gov

Contact Your Healthcare Provider
Contact your healthcare provider to determine the best treatment plan for you.

While most people experience minor symptoms, if you develop a high fever or trouble breathing, or your condition worsens, seek emergency care immediately.

Public Health Reporting
You may be contacted by public health officials.

If the BinaxNOW COVID-19 Ag Card Home Test result is Invalid, the user will receive the following:

Laura Test's COVID-19 test was invalid.

Follow-up COVID-19 testing may be needed.

BinaxNOW COVID-19 Test Details

Results Reported On
Dec 10, 2020 at 4:37 PM

Name
Laura Test

Test Result
Invalid

Lot
IDPIL0T1

Serial Number
7RAvI1Da50cJEnVkB89N9s

CDC Guidelines
- Wash your hands often
- Avoid close contact
- Cover your mouth and nose with a cloth face cover when around others
- Cover coughs and sneezes
- Clean and disinfect
- Monitor your health daily

Read more at CDC.gov
LIMITATIONS

- This test detects both viable (live) and non-viable SARS-CoV, and SARS-CoV-2. Test performance depends on the amount of virus (antigen) in the sample and may or may not correlate with viral culture results performed on the same sample.
- A negative test result may occur if the level of antigen in a sample is below the detection limit of the test.
- The performance of the BinaxNOW COVID-19 Ag Card Home Test was evaluated using the procedures provided in this product insert only. Modifications to these procedures may alter the performance of the test.
- False negative results may occur if a specimen is improperly collected or handled.
- False negative results may occur if inadequate extraction buffer is used (e.g., <6 drops).
- False negative results may occur if specimen swabs are not twisted within the test card.
- False negative results may occur if swabs are stored in their paper sheath after specimen collection.
- Positive test results do not rule out co-infections with other pathogens.
- False negative results are more likely after eight days or more of symptoms.
- Positive test results do not differentiate between SARS-CoV and SARS-CoV-2.
- Negative test results are not intended to rule in other non-SARS viral or bacterial infections.
- The presence of mupirocin may interfere with the BinaxNOW COVID-19 Ag test and may cause false negative results.
- Negative results are presumptive, do not rule out COVID-19 infection and it may be necessary to obtain additional testing with a molecular assay, if needed for patient management.
- Performance of nasal swabs collected by an adult caregiver from a pediatric patient has not been determined, a study to support use in a pediatric population is ongoing.
- Performance of nasal swabs collected from patients without symptoms or other epidemiological reasons to suspect COVID-19 infection or for serial screening, when tested twice over three days with at least 24 hours but no more than 48 hours between tests has not been determined, a study to support use will be completed.
- Testing for asymptomatic individuals should be performed at least twice over three days, with at least twenty-four hours and no more than 48 hours between tests. You may need to purchase additional tests to perform this serial (repeat) testing.
- There is a higher chance of false negative results with antigen tests than with laboratory-based molecular tests. This means that there is a higher chance this test will give you a negative result when you have COVID-19.
- Serial testing (i.e., testing every day or every other day) is more likely to detect COVID-19, especially when you do not have any symptoms.
- If the differentiation of specific SARS viruses and strains is needed, additional testing, in consultation with state or local public health departments, is required.

PERFORMANCE CHARACTERISTICS

CLINICAL PERFORMANCE

Clinical performance characteristics of BinaxNOW COVID-19 Ag Card Home Test was evaluated in a multi-site prospective study in the U.S. A total of five (5) investigational sites throughout the U.S. participated in the study. To be enrolled in the study, patients had to be presenting at the participating study centers with suspected COVID-19 within 7 days of symptom onset. Each Subject was provided a BinaxNOW COVID-19 Ag Card Home Test. Under the observation and coaching of a clinical site staff member trained as a proctor, the Subject self-collected one (1) nasal swab and performed the BinaxNOW COVID-19 Ag Card Home Test. Test results were interpreted and recorded by the Subject or other home user and independently by the proctor. Parents of pediatric Subjects under the age of 14 or Legally Authorized Representatives of adult Subjects unable to perform self-collection collected one (1) nasal swab from the Subject, performed the BinaxNOW COVID-19 Ag Card Home Test, then interpreted and recorded the result for the patient.

An FDA Emergency Use Authorized real-time Polymerase Chain Reaction (RT-PCR) assay for the detection of SARS-CoV-2 was utilized as the comparator method for this study.

The performance of BinaxNOW COVID-19 Ag Card Home Test was established with 356 nasal swabs collected from individual symptomatic patients (within 7 days of onset) who were suspected of COVID-19.

BinaxNOW™ COVID-19 Ag Card Home Test - Lay User Performance within 7 days of symptom onset against the Comparator Method

<table>
<thead>
<tr>
<th></th>
<th>BinaxNOW™ COVID-19 Ag Card Home Test</th>
<th>Comparator Method</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Positive</td>
<td>Negative</td>
</tr>
<tr>
<td>Positive</td>
<td>102</td>
<td>4</td>
</tr>
<tr>
<td>Negative</td>
<td>3</td>
<td>227</td>
</tr>
<tr>
<td>Total</td>
<td>125</td>
<td>231</td>
</tr>
</tbody>
</table>

Positive Agreement: 102/125 81.6% (95% CI: 73.7% - 88.0%)
Negative Agreement: 227/231 98.3% (95% CI: 95.6% - 99.5%)

* 3 samples generated an invalid BinaxNOW COVID-19 Ag Card Home Test result (1.89% (95% CI of 0.05% to 10.07%) invalid rate)
**BinaxNOW™ COVID-19 Ag Card Home Test - Proctor Performance within 7 days of symptom onset against the Comparator Method**

<table>
<thead>
<tr>
<th>BinaxNOW™ COVID-19 Ag Card Home Test</th>
<th>Comparator Method</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive</td>
<td>Positive</td>
</tr>
<tr>
<td>Positive</td>
<td>105</td>
</tr>
<tr>
<td>Negative</td>
<td>20</td>
</tr>
<tr>
<td>Total</td>
<td>125</td>
</tr>
<tr>
<td>Positive Agreement: 105/125 = 84.0% (95% CI: 76.4% - 89.9%)</td>
<td></td>
</tr>
<tr>
<td>Negative Agreement: 226/230 = 98.3% (95% CI: 95.6% - 99.5%)</td>
<td></td>
</tr>
</tbody>
</table>

**Hazardous Ingredients for the Reagent Solution**

<table>
<thead>
<tr>
<th>Chemical Name/CAS</th>
<th>GHS Code for each Ingredient</th>
<th>Concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium Azide/26628-22-8</td>
<td>Acute Tox. 2 (Oral), H300 Acute Tox. 1 (Dermal), H310</td>
<td>0.0125%</td>
</tr>
</tbody>
</table>

The solution in the tube contains a hazardous ingredient (see table above). If the solution contacts the skin or eye, flush with plenty of water. If irritation persists, seek medical advice. [http://www.poison.org/contact-us or 1-800-222-1222](http://www.poison.org/contact-us or 1-800-222-1222).

**ANALYTICAL PERFORMANCE**

**Limit of Detection (Analytical Sensitivity)**

BinaxNOW COVID-19 Ag Card Home Test limit of detection (LOD) was determined by evaluating different concentrations of heat inactivated SARS-CoV-2 virus. Presumed negative natural nasal swab specimens were eluted in PBS. Swab eluates were combined and mixed thoroughly to create a clinical matrix pool to be used as the diluent. Inactivated SARS-CoV-2 virus was diluted in this natural nasal swab matrix pool to generate virus dilutions for testing.

Contrived nasal swab samples were prepared by absorbing 20 microliters of each virus dilution onto the swab. The contrived swab samples were tested according to the test procedure.

The LOD was determined as the lowest virus concentration that was detected at least 95% of the time (i.e., concentration at which at least 19 out of 20 replicates tested positive).

The BinaxNOW COVID-19 Ag Card Home Test LOD in natural nasal swab matrix was confirmed as 140.6 TCID₅₀/mL.

**Limit of Detection (LoD) Study Results**

<table>
<thead>
<tr>
<th>Concentration TCID₅₀/mL</th>
<th>Number Positive/Total</th>
<th>% Detected</th>
</tr>
</thead>
<tbody>
<tr>
<td>140.6</td>
<td>20/20</td>
<td>100%</td>
</tr>
</tbody>
</table>

Patient demographics, time elapsed since onset of symptoms for all patients enrolled in the above study, are presented in the table below. Positive results broken down by days since symptom onset:

<table>
<thead>
<tr>
<th>Days Since Symptom Onset</th>
<th>Cumulative RT-PCR Positive (+)</th>
<th>Cumulative BinaxNOW™ COVID-19 Ag Card Positive (+)</th>
<th>PPA</th>
<th>95% Confidence Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>21</td>
<td>19</td>
<td>90.5%</td>
<td>69.6% - 98.8%</td>
</tr>
<tr>
<td>2</td>
<td>57</td>
<td>47</td>
<td>82.5%</td>
<td>70.1% - 91.3%</td>
</tr>
<tr>
<td>3</td>
<td>89</td>
<td>72</td>
<td>80.9%</td>
<td>71.2% - 88.5%</td>
</tr>
<tr>
<td>4</td>
<td>104</td>
<td>86</td>
<td>82.7%</td>
<td>74.0% - 89.4%</td>
</tr>
<tr>
<td>5</td>
<td>111</td>
<td>93</td>
<td>83.8%</td>
<td>75.6% - 90.1%</td>
</tr>
<tr>
<td>6</td>
<td>119</td>
<td>100</td>
<td>84.0%</td>
<td>76.2% - 90.1%</td>
</tr>
<tr>
<td>7</td>
<td>125</td>
<td>102</td>
<td>81.6%</td>
<td>73.7% - 88.0%</td>
</tr>
</tbody>
</table>
Cross Reactivity (Analytical Specificity) and Microbial Interference

Cross reactivity and potential interference of BinaxNOW COVID-19 Ag Card Home Test was evaluated by testing 37 commensal and pathogenic microorganisms (8 bacteria, 14 viruses, 1 yeast and pooled human nasal wash) that may be present in the nasal cavity. Each of the organism, viruses, and yeast were tested in triplicate in the absence or presence of heat inactivated SARS-CoV-2 virus (45 TCID$_{50}$/swab). No cross-reactivity or interference was seen with the following microorganisms when tested at the concentration presented in the table below.

### Potential Cross-Reactant

<table>
<thead>
<tr>
<th>Potential Cross-Reactant</th>
<th>Test Concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adenovirus</td>
<td>1.0 x 10^⁵ TCID$_{50}$/mL</td>
</tr>
<tr>
<td>Human metapneumovirus (hMPV)</td>
<td>1.0 x 10^⁵ TCID$_{50}$/mL</td>
</tr>
<tr>
<td>Rhinovirus</td>
<td>1.0 x 10^⁵ PFU/mL</td>
</tr>
<tr>
<td>Enterovirus/Coxsackievirus B4</td>
<td>1.0 x 10^⁵ TCID$_{50}$/mL</td>
</tr>
<tr>
<td>Human coronavirus OC43</td>
<td>1.0 x 10^⁵ TCID$_{50}$/mL</td>
</tr>
<tr>
<td>Human coronavirus 229E</td>
<td>1.0 x 10^⁵ TCID$_{50}$/mL</td>
</tr>
<tr>
<td>Human coronavirus NL63</td>
<td>1.0 x 10^⁵ TCID$_{50}$/mL</td>
</tr>
<tr>
<td>Human parainfluenza virus 1</td>
<td>1.0 x 10^⁵ TCID$_{50}$/mL</td>
</tr>
<tr>
<td>Human parainfluenza virus 2</td>
<td>1.0 x 10^⁵ TCID$_{50}$/mL</td>
</tr>
<tr>
<td>Human parainfluenza virus 3</td>
<td>1.0 x 10^⁵ TCID$_{50}$/mL</td>
</tr>
<tr>
<td>Human parainfluenza virus 4</td>
<td>1.0 x 10^⁵ TCID$_{50}$/mL</td>
</tr>
<tr>
<td>Influenza A</td>
<td>1.0 x 10^⁵ TCID$_{50}$/mL</td>
</tr>
<tr>
<td>Influenza B</td>
<td>1.0 x 10^⁵ TCID$_{50}$/mL</td>
</tr>
<tr>
<td>Respiratory Syncytial Virus A</td>
<td>1.0 x 10^⁵ PFU/mL</td>
</tr>
<tr>
<td><strong>Bacteria</strong></td>
<td></td>
</tr>
<tr>
<td>Bordetella pertussis</td>
<td>1.0 x 10^⁶ cells/mL</td>
</tr>
<tr>
<td>Chlamydia pneumoniae</td>
<td>1.0 x 10^¹ IFU/mL</td>
</tr>
<tr>
<td>Haemophilus influenzae</td>
<td>1.0 x 10^⁵ cells/mL</td>
</tr>
<tr>
<td>Legionella pneumophila</td>
<td>1.0 x 10^⁵ cells/mL</td>
</tr>
<tr>
<td>Mycoplasma pneumoniae</td>
<td>1.0 x 10^¹ UI/mL</td>
</tr>
<tr>
<td>Streptococcus pneumoniae</td>
<td>1.0 x 10^⁵ cells/mL</td>
</tr>
<tr>
<td>Streptococcus pyogenes (group A)</td>
<td>1.0 x 10^⁵ cells/mL</td>
</tr>
<tr>
<td>Mycobacterium tuberculosis</td>
<td>1.0 x 10^⁵ cells/mL</td>
</tr>
<tr>
<td>Staphylococcus aureus</td>
<td>1.0 x 10^⁶ org/mL</td>
</tr>
<tr>
<td>Staphylococcus epidermidis</td>
<td>1.0 x 10^⁶ org/mL</td>
</tr>
<tr>
<td>Pooled human nasal wash</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Yeast</strong></td>
<td></td>
</tr>
<tr>
<td>Candida albicans</td>
<td>1.0 x 10^⁵ cells/mL</td>
</tr>
</tbody>
</table>

To estimate the likelihood of cross-reactivity with SARS-CoV-2 virus in the presence of organisms that were not available for wet testing, *in silico* analysis using the Basic Local Alignment Search Tool (BLAST) managed by the National Center for Biotechnology Information (NCBI) was used to assess the degree of protein sequence homology.

- For *P. jirovecii* one area of sequence similarity shows 45% homology across 18% of the sequence, making cross-reactivity in the BinaxNOW COVID-19 Ag Card highly unlikely.
- No protein sequence homology was found between *M. tuberculosis*, and thus homology-based cross-reactivity can be ruled out.
- The comparison between SARS-CoV-2 nucleocapsid protein, MERS-CoV and human coronavirus HKU1 revealed that cross-reactivity cannot be ruled out. Homology for HKU1 and MERS-CoV is relatively low, at 37.8% across 95% of the sequence and 57.14% across 87% of the sequence, respectively.

### High Dose Hook Effect

No high dose hook effect was observed when tested with up to a concentration of 1.6 x 10^⁵ TCID$_{50}$/mL of heat inactivated SARS-CoV-2 virus with the BinaxNOW COVID-19 Ag Card Home Test.
Endogenous Interfering Substances

The following substances, naturally present in respiratory specimens or that may be artificially introduced into the nasal cavity or nasopharynx, were evaluated with the BinaxNOW COVID-19 Ag Card Home Test at the concentrations listed below and were found not to affect test performance.

<table>
<thead>
<tr>
<th>Substance</th>
<th>Active Ingredient</th>
<th>Concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endogenous</td>
<td>Mucin</td>
<td>2% w/v</td>
</tr>
<tr>
<td></td>
<td>Whole Blood</td>
<td>1% v/v</td>
</tr>
<tr>
<td>OTC Nasal Drops</td>
<td>Phenylephrine</td>
<td>15% v/v</td>
</tr>
<tr>
<td>OTC Nasal Gel</td>
<td>Sodium Chloride</td>
<td>5% v/v</td>
</tr>
<tr>
<td>OTC Nasal Spray 1</td>
<td>Cromolyn</td>
<td>15% v/v</td>
</tr>
<tr>
<td>OTC Nasal Spray 2</td>
<td>Oxymetazoline</td>
<td>15% v/v</td>
</tr>
<tr>
<td>OTC Nasal Spray 3</td>
<td>Fluconazole</td>
<td>5% v/v</td>
</tr>
<tr>
<td>Throat Lozenge</td>
<td>Benzoic Acid, Menthol</td>
<td>0.15% w/v</td>
</tr>
<tr>
<td>OTC Homeopathic Nasal Spray 1</td>
<td>Galphimia glauca, Sabadilla, Luffa opperculata</td>
<td>20% v/v</td>
</tr>
<tr>
<td>OTC Homeopathic Nasal Spray 2</td>
<td>Zincum gluconium (i.e., Zicam)</td>
<td>5% v/v</td>
</tr>
<tr>
<td>OTC Homeopathic Nasal Spray 3</td>
<td>Alkalol</td>
<td>10% v/v</td>
</tr>
<tr>
<td>OTC Homeopathic Nasal Spray 4</td>
<td>Fluticasone Propionate</td>
<td>5% v/v</td>
</tr>
<tr>
<td>Sore Throat Phenol Spray</td>
<td>Phenol</td>
<td>15% v/v</td>
</tr>
<tr>
<td>Anti-viral Drug</td>
<td>Tamiflu (Oseltamivir Phosphate)</td>
<td>0.5% w/v</td>
</tr>
<tr>
<td>Antibiotic, Nasal Ointment</td>
<td>Mupirocin¹</td>
<td>0.25% w/v</td>
</tr>
<tr>
<td>Antibacterial, Systemic</td>
<td>Tobramycin</td>
<td>0.0004% w/v</td>
</tr>
</tbody>
</table>

¹ Testing demonstrated false negative results at concentrations of 5 mg/mL (0.5% w/v). Standard dose of nasal ointment: 20 mg (2% w/w) of mupirocin in single-use 1-gram tubes.

Human Factors Study

Abbott conducted a human factor’s study to evaluate whether home user patients or caregivers (lay user) could perform the test and accurately interpret test results from the BinaxNOW COVID-19 Ag Card under the supervision of a trained proctor.

In this study, a total of 31 lay users, age 15 and older with either good or corrected vision (farsighted or wear bifocals) participated in a 45-minute session including an introduction, a product overview, and simulated use cases of BinaxNOW COVID-19 Ag Card test result interpretation. Participants were asked to read and interpret a panel of 9 different BinaxNOW COVID-19 Ag Card test results, including high positive, low positive, negative and invalid under the guidance of a virtual proctor. Participants and virtual proctors were blinded to the test card results.

22/30 participants described the process of reading and interpreting the test card results as being easy. However, 8/30 of the participants commented that it was difficult to see some of the fainter line conditions.

A total of 270 trials were recorded in this study. Participants were able to perceive and interpret the results correctly for 239 trials, or 89% of the time. Positive results with stronger intensity lines were easier to read than the positive lines with less intensity. As the line intensity became fainter, the ability to read the result correctly ranged from 83% to 60%, with an overall rate of 70%.

After the human factors evaluation, participants were asked for their overall impressions of the instructional materials they were provided. Nearly all participants (29/30) thought the instructions were straightforward and easy to understand and follow.

Based on the learnings from this study improvements were made to the Quick Reference Guide and Proctor training.

Usability Study

Abbott conducted a study to evaluate whether a home user can follow instructions from a trained proctor through a virtual platform and successfully perform the test steps for the BinaxNOW COVID-19 Ag Card test, including nasal swab collection at home, and correctly interpreting the results.

60 home users, including individuals (n=30) and caregivers (n=30), participated in the study. Each individual or caregiver pair participated in a 45-minute session with a single proctor. The usability evaluation session included one simulated use of the BinaxNOW COVID-19 Home Test Kit in which a user was already connected with a proctor, knowledge tasks, and opportunities to provide feedback.

96.7% (58 out of 60) home users produced a valid result (all negative) and 2 participants produced an invalid result. (The causes of the invalid tests were insufficient amount of reagent added, and damage to the test strip). 58 out of 60 participants interpreted their test result correctly and 2 participants interpreted their result incorrectly (where they perceived a faint line in the sample window (as positive) when there was none (all results were verified by the study moderator).

The individual home use group completed 96.8% (1103/1140) of the total tasks/steps correctly. The caregiver home user group completed 97.3% (1109/1140) of the total tasks/steps correctly. The most common use errors observed during critical tasks included incorrectly swabbing the nostril to obtain a nasal sample and contacting the test strip with the hands or with the surface.
90% (56 out of 60) of the home (individual and caregiver) participants had positive impressions of the BinaxNOW COVID-19 Ag Card Home Test Kit. The test was perceived as being easy to use. The mixed feedback from three home user participants included that some of the labeling on the different components was confusing and one participant reported that they would not be comfortable performing this test without a medical professional present.

88% (53 out of 60) participants stated the Quick Reference Guide (QRG) shown on the screen while the participant performed simulated use of the BinaxNOW COVID-19 Ag Card Home test was clear and easy to understand. 54 out of 60 participants felt their proctor that helped guide them through the workflow was helpful and provided clear instructions.

**SYMBOLS**

<table>
<thead>
<tr>
<th>Symbol</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="temp_limit.png" alt="Temp Limit" /></td>
<td>This symbol indicates that the product has a temperature limitation.</td>
</tr>
<tr>
<td><img src="total_tests.png" alt="Total Tests" /></td>
<td>This symbol indicates the total number of tests provided in the kit box.</td>
</tr>
<tr>
<td><img src="single_use.png" alt="Single Use" /></td>
<td>This symbol indicates that the product is for single use only. It is not to be re-used.</td>
</tr>
<tr>
<td><img src="ivd.png" alt="IVD" /></td>
<td>For In Vitro Diagnostic Use.</td>
</tr>
<tr>
<td><img src="instructions.png" alt="Instructions" /></td>
<td>This symbol indicates that you should consult the instructions for use.</td>
</tr>
<tr>
<td><img src="catalog_number.png" alt="Catalog Number" /></td>
<td>This symbol indicates the product’s catalog number.</td>
</tr>
<tr>
<td><img src="manufacturer.png" alt="Manufacturer" /></td>
<td>This symbol indicates the name and location of the product manufacturer.</td>
</tr>
</tbody>
</table>

**TECHNICAL SUPPORT ADVICE LINE**

Further information can be obtained from your Telehealth provider, or by contacting Technical Support on:

**US**

+1 800 257 9525  

ts.scr@abbott.com